| Document |
Document Title |
|
WO/1997/024285A1 |
The preparation of water-insoluble, bactericidal, peroxide-containing products, by reaction of magnesium acetate with hydrogen peroxide, and products obtained are disclosed. Processes for application and deposition of these reaction prod...
|
|
WO/1997/020790A1 |
The invention concerns solutions of alkoxides containing titanium and/or zirconium and/or hafnium and magnesium and/or calcium and/or strontium and/or barium of general formula (I): [MII(OR)2-y(OR1)y]n.[MIV(OR1)4-z(OR)z], in which: MII m...
|
|
WO/1997/019081A1 |
Metalated bacteriochlorophylls of the formula [M]-BChl, wherein M is a metal atom selected from divalent Pd, Co, Ni, Cu, Zn and Mn, trivalent Fe, Mn and Cr, and tetravalent Sn and Pt, and Bchl represents the residue of a demetalated natu...
|
|
WO/1997/015602A1 |
Metal complexes useful as olefin polymerization catalysts corresponding to formula (I), wherein L is a delocalized, 'pi'-bonded group that is bound to M, containing up to 50 nonhydrogen atoms; M is a metal of Group 3, 4 or the Lanthanide...
|
|
WO/1997/008121A1 |
The present invention provides a continuous melt process for the preparation of a unique zinc oxide/pentaerythritol chemical product that can be used as a stabilizer. The process comprises the steps of providing a continuous processor ha...
|
|
WO/1997/006831A1 |
The present invention is directed to complexes represented by formula (I), wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, R'9, M, X, Y, Z and n are defined herein for use as contrast agents in ...
|
|
WO/1996/040690A1 |
A metalorganic complex of the formula MAYX, wherein M is a y-valent metal; A is a monodentate or multidentate organic ligand coordinated to M which allows complexing of MAy with X; y is an integer having a value of 2, 3 or 4; each of the...
|
|
WO/1996/040684A1 |
A process is described for preparing a compound of formula (I), or a salt thereof; wherein X is a protecting group; and R1, R2, R3 and R4 are each independently hydrogen, C1-6alkyl or C1-6perfluoroalkyl; R5 is hydrogen or, when n is 1, R...
|
|
WO/1996/039193A2 |
The invention relates to novel targeting drug agents that are targeted for entry into the mitochondria. More specifically, the agents are cisplatin derivatives called mitoplatins which are useful as anti-tumor agents. Mitoplatins are nam...
|
|
WO/1996/028449A1 |
Porphyrazine compounds having moieties substituted at the eight peripheral 'beta'-pyrrole positions are disclosed. The porphyrazine compounds have general structural formula (V), wherein M is H2 or a metal capable of complexing with the ...
|
|
WO/1996/017844A1 |
Strapped porphyrins and electron-deficient porphyrins are provided, as well as processes and intermediates for their preparation. In certain embodiments, such compounds are prepared by nucleophilic displacement of leaving groups from met...
|
|
WO/1996/013504A1 |
A 'beta','beta''-dihydroxy meso-substituted chlorin, bacteriochlorin or isobacteriochlorin compound having formula (I) or (II), wherein M is a metal. A novel method for synthesizing the compound of formula (I) or (II) comprises the steps...
|
|
WO/1996/011907A1 |
Method of enhancing the water solubility of dry zinc and/or manganese methionine complex salts by reacting a water soluble zinc and/or manganese salt with methionine in the presence of ferric ion with the amount being between at least 15...
|
|
WO/1996/006101A1 |
A palatable metal amino acid chelate for administration to humans and other warm-blooded animals is disclosed wherein there are sufficient ligands to provide ionic and coordinate covalent bonds equal to the coordination number of the cen...
|
|
WO/1995/030681A1 |
Single or multi-nuclear metal complexes [LnMmXp]zY, in which M is manganese in the oxidation number (II, III, IV, V and/or VI), copper in the oxidation number (I and/or II), cobalt in the oxidation number (II and/or III) or zinc in the o...
|
|
WO/1995/029916A1 |
Electron-deficient porphyrins are provided, as well as processes and intermediates for their preparation. In preferred embodiments, the electron-deficient porphyrins are prepared by condensing pyrrole derivatives and removing water thus ...
|
|
WO/1995/026965A1 |
The present invention relates to an improved process for making heterocyclic compounds suitable as intermediate products for making D-(+)-biotin and a process for making D-(+)-biotin itself.
|
|
WO/1995/013282A1 |
A metalorganic chemical vapor deposition (MOCVD) method for depositing an F-series metal onto a semiconductor or other substrate or for incorporating nitrogen as a p-type dopant in Group II-VI semicconductor materials. The MOCVD method u...
|
|
WO/1995/005150A1 |
Hydroxy salts of the formula [M(OH)(2-a)]a+ Xb-a/b . zH2O, where M is zinc, copper or a mixture of the two and X denotes anions at least some of which display ultraviolet absorption over at least a portion of the wavelength range from 29...
|
|
WO/1995/001977A1 |
A novel compound form of magnesium omeprazole useful in the manufacture of pharmaceutical formulations, the use of the product and the process for its production are described.
|
|
WO/1994/027988A1 |
The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl
]sulfinyl]-1H_-benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl
]su...
|
|
WO/1994/022576A1 |
The use of intramolecularly stabilized organometallic compounds as components of coordination catalyst systems is disclosed, as well as corresponding coordination catalyst systems and a process for preparing polymers by coordination poly...
|
|
WO/1994/018145A1 |
Method for forming metal alkyl compounds by the direct combination of metal halide, lithium metal, and alkyl or aryl halide and for purifying metal alkyl compounds by repeated sublimation/pumping cycles. The method can be used to produce...
|
|
WO/1994/017083A1 |
A compound which is, or which contains at least two repeating units, represented by formula (1): (LnMn1)n2An3 or by formula (2): (LnMn1)n2L'n4An3 wherein L and L' are the same or different bis-lactam ligand represented by formula (3) or ...
|
|
WO/1994/011387A2 |
Disclosed is a new process for producing finasteride which involves reacting the magnesium halide salt of 17beta-carboalkoxy-4-aza-5alpha-androst-1-en-3-one with t-butylamino magnesium halide, present in at least a 2:1 molar ratio to the...
|
|
WO/1994/004141A1 |
Vitamin and mineral absorption in warm-blooded animals is promoted by means of a class of vitamin chelates where at least one of the bonds between the metal ion and the vitamin ligand is formed between the ion and an electron rich pi-clo...
|
|
WO/1994/004614A1 |
Porphyrins substituted with, for example, vinyl and acetylene groups are provided, along with polymers containing the same. In preferred embodiments, the substituted porphyrins are prepared by coupling halogenated porphyrins with anionic...
|
|
WO/1993/025558A1 |
2-Aminoethanesulfonic acid/zinc complex compound represented by formula (I), a process for the production thereof, and antihepatitis drug, hepatic function ameliorant and antiulcer drug each containing the compound [I] as the active ingr...
|
|
WO/1993/024263A1 |
Novel zerovalent metal species and organometallic reagents are disclosed. The zerovalent metal species are directly produced by reaction of a reducing agent on a metal cyanide salt. Preferably, the zerovalent metal species are directly p...
|
|
WO/1993/022472A1 |
The use of organo-metallic compounds that contain as metallic component an element of the 2nd or 4th main group, of the 1st-8th sub-group, of the rare earths or bismuth, is disclosed for precipitating the metal on substrates, as well as ...
|
|
WO/1993/020088A1 |
Mixed ligand metal complexes of nitric oxide-nucleophile adducts, useful as cardiovascular agents of the formula KA, wherein A is [(M)x'x(L)y(R1R2N-N2O2)z], and M is a pharmaceutilcally acceptable metal, or where x is at least two, M may...
|
|
WO/1993/015086A1 |
A novel zerovalent zinc species and an organozinc reagent are disclosed. The zerovalent zinc species is directly produced by reaction of a reducing agent on a zinc salt, preferably Zn(CN)¿2?. The organozinc reagent results from the reac...
|
|
WO/1993/014095A1 |
A 2-aminoethanesulfonic acid/zinc complex represented by general formula (I) (wherein M represents an alkali metal atom), a process for the production thereof from 2-aminoethanesulfonic acid, and the use thereof for treating hepatitis an...
|
|
WO/1993/012121A1 |
Process for the preparation of compounds of the formula (I): Y-Mg-X wherein Y is allyl, or an optionally substituted phenyl or optionally substituted benzyl group, and X is a halogen, by reaction of a compound of the formula (II): Y-X wh...
|
|
WO/1993/011135A1 |
The present invention relates to processes for preparing sunscreen complexes, and more particularly to sunscreen metal complexes, having enhanced UVA absorption. These complexes comprise a dibenzoylmethane UVA-absorbing sunscreen complex...
|
|
WO/1993/010124A1 |
Di-alkyl compounds of a Group 2b metal are prepared in a process in which a Group 2b metal is reacted with an alkyl halide in the presence of magnesium to obtain the di-alkyl compound of the Group 2b metal and magnesium halide. Di-alkyl ...
|
|
WO/1993/006110A1 |
The magnesium complexes of cyclic hydrocarbons and conjugated dienes, such as 1,2-dimethylenecycloalkanes and 1,3-butadienes, are readily prepared in high yields using highly reactive magnesium. Reactions of these (2-butene-1,4-diyl)magn...
|
|
WO/1993/004072A1 |
Novel metal beta-diketonates are disclosed, including coordination complexes thereof with inorganic and organic donor ligands, useful in CVD applications. These are metal beta-diketonates of the formula: M{R1C(O)CHC(O)R2}x where M is a m...
|
|
WO/1993/003044A1 |
A soluble highly reactive form of calcium, prepared from Ca(II) salts and a reducing agent in ethereal, polyethereal, or hydrocarbon solvents, is presented. This form of calcium can be used in the preparation of organocalcium reagents. T...
|
|
WO/1993/002086A1 |
Process for the preparation of compounds of the formula (I): Y-Mg-X wherein Y is an optionally substituted phenyl or benzyl, and X is a halogen, by reaction of a compound of the formula (II): Y-X wherein Y and X have the meanings given a...
|
|
WO/1992/020694A1 |
The use of magnesium oxide of specified, low, reactivity in a process for the production of overbased magnesium sulphonates, together with the introduction of water and an alcohol, into the reaction mixture during carbonation, makes it p...
|
|
WO/1992/019623A1 |
A novel zerovalent copper species and an organocopper reagent are disclosed. The zerovalent copper species is directly produced by reaction of a reducing agent with a combination of copper cyanide or halide and an alkali metal halide sal...
|
|
WO/1992/016533A1 |
A simple process is disclosed for producing alkoxymagnesium halogenides in a single step by stoichiometrically reacting magnesium that has been pre-activated by a magnesiumalkyl compound with an equimolar mixture of alkylhalogenide and a...
|
|
WO/1992/009549A1 |
A process for the preparation of a zinc-containing polymeric material which process includes providing a divalent metal compound including zinc; a polyhydroxy compound; and a catalyst; mixing the divalent metal compound and the polyhydro...
|
|
WO/1992/006945A1 |
Basic barium carboxylates of branched chain aliphatic monocarboxylic acids having 6 to 9 carbon atoms are disclosed. The carboxylates may be used, inter alia, as stabilizers for polyvinyl chloride.
|
|
WO/1991/010645A2 |
There are provided novel chelating agents useful in the preparation of contrast media for diagnostic imaging or of radiotherapeutic or detoxification compositions.
|
|
WO/1991/010655A1 |
The invention relates to partially novel metal complexes, salts and double salts of 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane compounds of formula (I), wherein Q1 and Q2 mean hydrogen or a group of formula (III), in the groups of form...
|
|
WO/1991/009525A1 |
Compositions of a quinolone carboxylic acids useful for oral or parenteral administration to a human or veterinary patient are disclosed which comprise quinolone carboxylic acid--metal ion--acid complexes in combination with a physiologi...
|
|
WO/1991/005762A1 |
There are disclosed polychelant compounds, that is multi-site metal chelating agents, and chelates formed therewith. The polychelants and especially their paramagnetic metal, heavy metal or radioactive metal polychelates are particularly...
|
|
WO/1990/015112A1 |
A process is provided for making bulk calcium magnesium acetate in a substantially pure crystalline form by forming a solution of calcium, magnesium and acetate ions in a substantially non-aqueous solvent and maintaining the solution at ...
|
